Want to see KR:011000 full AI Analyst Report?
011000 Stock Chart & Stats
₩2670.00
₩0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range₩2,600.00 - ₩12,450.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
₩48.51B
Enterprise Value₩76.53B
Total Cash (Recent Filing)₩6.82B
Total Debt (Recent Filing)₩34.15B
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11847.90
Shares Outstanding18,176,582
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.82
Price to Sales (P/S)1.40
P/FCF Ratio-2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO ContinuitySecuring a long-term Texas lease protects the space needed for VGXI’s CDMO activity and reduces facility uncertainty. Starting a dedicated line at Plant 1 also allows production to begin without waiting for the delayed Conroe facility plan.
Strategic Facility OptionPreserving the buyback option keeps open a path to regain control of a strategically important manufacturing facility. If completed, ownership could support future CDMO capacity and operational control, although the option requires substantial staged payments.
Positive EquityPositive shareholders’ equity provides some balance-sheet support despite recent deterioration and ongoing losses. This is not a substitute for profitability, but it indicates the company has not yet exhausted its equity base and retains a foundation for restructuring or recovery efforts.
Bears Say
Shrinking RevenueMulti-year revenue contraction signals weakening commercial scale and makes it harder to absorb fixed operating costs. The sharp 2025 decline is especially concerning because a smaller revenue base reduces the potential for operating leverage and limits resources available for product and business development.
Persistent LossesNegative gross profit means costs exceeded revenue before operating expenses, indicating that the core economics are not currently sustainable. Continued large net losses further weaken earnings quality and make a durable path to profitability dependent on substantial operational improvement.
Cash Burn And LeverageOngoing operating cash burn reduces the funds available to maintain operations, invest in growth, or meet obligations internally. At the same time, higher leverage increases financial risk and reduces flexibility if losses continue, particularly as the balance sheet has weakened recently.
GeneOne Life Science, Inc. News
011000 FAQ
What was GeneOne Life Science, Inc.’s price range in the past 12 months?
GeneOne Life Science, Inc. lowest stock price was ₩2600.00 and its highest was ₩12450.00 in the past 12 months.
What is GeneOne Life Science, Inc.’s market cap?
GeneOne Life Science, Inc.’s market cap is ₩48.51B.
When is GeneOne Life Science, Inc.’s upcoming earnings report date?
GeneOne Life Science, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 18 days.
How were GeneOne Life Science, Inc.’s earnings last quarter?
GeneOne Life Science, Inc. released its earnings results on Aug 14, 2026. The company reported -₩1044.903 earnings per share for the quarter.
Is GeneOne Life Science, Inc. overvalued?
According to Wall Street analysts GeneOne Life Science, Inc.’s price is currently Undervalued.
Does GeneOne Life Science, Inc. pay dividends?
GeneOne Life Science, Inc. does not currently pay dividends.
What is GeneOne Life Science, Inc.’s EPS estimate?
GeneOne Life Science, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GeneOne Life Science, Inc. have?
GeneOne Life Science, Inc. has 18,176,582 shares outstanding.
What happened to GeneOne Life Science, Inc.’s price movement after its last earnings report?
GeneOne Life Science, Inc. reported an EPS of -₩1044.903 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GeneOne Life Science, Inc.?
Currently, no hedge funds are holding shares in KR:011000
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GeneOne Life Science, Inc.
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.
Technical Analysis
Pharmicell Co., Ltd
―
Samsung Epis Holdings Co., Ltd.
―
ToolGen Incorporated
―
SK bioscience Co.,Ltd.
―
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
―